Hepion (HEPA) Director Danina Fisher Receives 299,000-Share Award

What Happened Danina Fisher, a director of Hepion Pharmaceuticals, received a grant/award of 299,000 derivative shares reported on Form 4. The filing lists an acquisition price of $0.00 for the shares (the Form shows $0 total value for the acquisition). This was an award (not an open-market purchase or sale) and is typically a form of compensation rather than a direct market buy.

Key Details

• Transaction date: 2026-08-19; Form 4 filed: 2026-08-21 (filed within the two-business-day window).
• Transaction type/code: Award/Grant (A) of derivative securities.
• Shares acquired: 299,000; reported acquisition price: $0.00 (total acquisition value shown as $0).
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes/plan info: Filing does not disclose a 10b5-1 plan, tax withholding, or other special footnotes.

Context An "A" (award/grant) of derivative shares often reflects compensation (e.g., restricted stock or RSUs) and does not necessarily signal a personal purchase decision or immediate intent to sell. Because the filing shows an acquisition price of $0, the market value of the award is not provided in the Form 4 and would require multiplying the grant size by the market price on the grant date to estimate economic value. The Form 4 appears to have been filed on time.